Hillrom to acquire Breathe Tech and its wearable ventilator for $130M

The $130 million cash deal would see Breathe’s Life2000 non-invasive air system added to Hillrom’s respiratory care portfolio. (Kritchanut/iStock/Getty Images Plus/Getty Images)

Hillrom has moved to pick up former Fierce 15 winner Breathe Technologies, maker of a wearable ventilator for people with lung conditions such as chronic obstructive pulmonary disease. 

The $130 million cash deal would see Breathe’s Life2000 non-invasive air system added to Hillrom’s respiratory care portfolio, broadening the company’s reach in COPD as well as interstitial lung disease, restrictive thoracic disorder and rehabilitation following a lung transplant.


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

The ventilator unit, which weighs about a pound, can be worn on a belt or waistband and has a four-hour battery life. It can be connected to a separate, stationary compressor for use inside the home, with tubing up to 50 feet long, or used alone outside the home while connected to an alternate pressure source.

RELATED: FierceMedicalDevices’ 2014 Fierce 15 | Breathe Technologies

"The acquisition of a highly differentiated, wearable non-invasive ventilation technology provides an exciting growth platform that utilizes our direct Respiratory Care commercial channel and business model," Hillrom President and CEO John Groetelaars said in a statement. 

Breathe's Life2000 ventilator
and compressor. (Breathe)

RELATED: Hillrom debuts new handheld telehealth eye camera for diabetic retinopathy screening

"This transaction represents another example of our plan to strategically deploy capital with a disciplined approach toward higher-growth and higher-margin businesses by expanding into the disruptive new category of non-invasive ventilation," Groetelaars added. 

Hillrom expects to close the deal during the fourth quarter of its 2019 fiscal year. The other products in its respiratory portfolio include a variety of airway clearance systems, including wearable and acute care versions, as well as nebulizer support.

Suggested Articles

The FDA approved the first spinal tether to correct the most common form of scoliosis—a ropelike implant that pulls the vertebrae into shape.

Agilent launched a new analyzer for research that observes cell behavior in real time while also collecting biosensor information.

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy.